Year: 2020
Frontline Niraparib, Bevacizumab Shows Activity In Certain Patients With Advanced Ovarian Cancer
Targeted Oncology (4/13, Columbus) reports, “Frontline niraparib (Zejula) in addition to bevacizumab (Avastin) as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response (PR) to frontline platinum-based chemotherapy with bevacizumab,” phase 2 data show. Findings were issued for the virtual SGO 2020 Annual Meeting. […]
Trastuzumab Addition Improves Survival In HER2-Positive Uterine Serous Carcinoma
(4/10, Rosa) reported, “The addition of trastuzumab (Herceptin) to carboplatin and paclitaxel resulted in a significant survival benefit in women with advanced or recurrent, HER2-positive uterine serous carcinoma, with the greatest benefit observed in those with stage III/IV disease who received the regimen up front,” updated phase 2 data demonstrate. In addition, the regimen “led […]
BRCA Testing Rates Have Increased In Ovarian Cancer, Although Researchers Find The Rates To Still Be Suboptimal
Cancer Therapy Advisor (4/1, Moench) reports that “results of a retrospective analysis of real-world clinical data from patients with ovarian cancer showed a temporal trend for increased rates of BRCA testing in the setting of ovarian cancer, although BRCA testing rates remained suboptimal,” according to findings that “were submitted to the Society of Gynecologic Oncology (SGO) […]
African-American Women Are More Likely To Have Uterine Cancer Characterized As Serous Carcinoma As Well As A Higher Frequency Of TP53-Mutated Endothelial Carcinoma Compared With White Women
Cancer Therapy Advisor (3/31, Moench) reports that “results of a tumor profiling study of uterine cancer specimens revealed that African-American women were significantly more likely to have uterine cancer characterized as serous carcinoma as well as a higher frequency of TP53-mutated endothelial carcinoma compared with white women.” The “findings were submitted to the Society of Gynecologic […]
Women With Early-Stage SCC Of Vulva, With Negative SLN At Time Of Surgery, May Have Low Risk Of Recurrent Disease In Groin, Study Suggests
Cancer Therapy Advisor (3/30, Moench) reports “results of a large prospective observational study that followed women with early-stage squamous cell carcinoma (SCC) of the vulva characterized by a negative sentinel lymph node biopsy (SLN) at the time of surgery showed these patients to have a low risk of recurrent disease in the groin.” In the study, […]
Researchers Say Combination Of Lenvatinib And Pembrolizumab Showed “Compelling Efficacy” For Treatment Of Advanced Endometrial Carcinoma
MedPage Today (3/26, Jenkins) reports researchers found in a phase 1b/2 trial that the combination of lenvatinib and pembrolizumab showed “compelling efficacy” for the treatment of “advanced endometrial carcinoma, regardless of tumor microsatellite instability status.” The researchers found “a 38% objective response rate at 24 weeks among the 108 women with advanced endometrial carcinoma treated […]
Ovarian Cancer News
Leading the News Cellular Recycling Genes Associated With Ovarian Tumor Formation Ovarian Cancer News Today (3/23, Bryson) reports that research in mice indicates that “disrupting genes essential for the cellular recycling process known as autophagy increases the frequency of mutations during cell division and promotes the formation of ovarian cancer tumors.” The research was published in PLOS Genetics […]
Significant Number Of Older Women With Breast Cancer May Have Genetic Mutations That Put Them At Risk Of Ovarian, Other Cancers
HealthDay (3/10, Gordon) reports, “A significant number of older women with breast cancer may have genetic mutations that put them at risk of additional cancers, particularly ovarian cancer, a new study finds.” In the study, published March 10 in the Journal of the American Medical Association, “the researchers said that as many as one in 40 postmenopausal women […]